Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
$7.26
-$0.25(-2.12%)
At close: 4:00 PM EST
$7.26
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$4.05 - $13.01
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$242.09M
Enterprise Value$33.00M
Total Cash (Recent Filing)$134.81M
Total Debt (Recent Filing)$40.12M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 03, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding46,465,916
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)1.24
Price to Sales (P/S)2.97
P/FCF Ratio-10.58
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$6.00Price Target Upside-17.36% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQuanterix reported 3Q25 results that were a touch above estimates and FacSet consensus.
Product DevelopmentManagement has launched over 25 assays in the last two years, leading to a more rapid menu expansion.
Synergies And IntegrationQuanterix remains on track to implement $85 million in annual merger synergies.
Bears Say
Funding And Biopharma ChallengesResults were impacted by continued NIH funding uncertainty and headwinds in biopharma.
Market CompetitionQTRX is starting to lag behind competitors, with Fujirebio's BBM already FDA approved, and QTRX does not expect FDA approval until 2026.
Revenue GuidanceThese positives are somewhat dampened by a 4Q implied revenue guide that is ~(6%) below consensus.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.05 and its highest was $13.01 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $242.09M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Mar 03, 2026 which is in 93 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Nov 10, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.272.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Overvalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.45.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 46,465,916 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-17.36% Downside)
$6.00 (-17.36% Downside)
Hedge Fund Trend
Decreased
By 234.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-29.28%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation (QTRX) is a life sciences company that focuses on advancing health care by providing innovative diagnostic solutions. The company operates within the biotechnology and diagnostics sectors, specializing in ultra-sensitive biomarker detection technology. Quanterix's core products include the Simoa (Single Molecule Array) platform, which enables researchers and clinicians to measure low-abundance biomarkers with high sensitivity and specificity. This technology is instrumental in areas such as neurology, oncology, and infectious diseases, facilitating early disease detection and monitoring.
QTRX Company Deck
QTRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong execution in revenue growth and successful integration of Akoya, contributing to a positive cash position and early momentum in diagnostics. However, challenges remain due to declines in core Simoa revenue and weaknesses in U.S. academic and pharmaceutical markets, compounded by the ongoing government shutdown. Despite these challenges, the company is positioned well for future growth with early commercial and cross-selling momentum.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$6.00
▼(-17.36% Downside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.31% Insiders
14.76% Mutual Funds
30.68% Other Institutional Investors
37.40% Public Companies and Individual Investors